Page last updated: 2024-10-27

fluorouracil and Hypopharyngeal Cancer

fluorouracil has been researched along with Hypopharyngeal Cancer in 111 studies

Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.

Research Excerpts

ExcerptRelevanceReference
"We present the case of a patient with a locally advanced hypopharyngeal carcinoma who developed a severe cytomegalovirus (CMV) colitis after his first chemotherapy course with 5-fluorouracil (5-FU), docetaxel and cisplatin."7.70Cytomegalovirus colitis after administration of docetaxel-5-fluorouracil-cisplatin chemotherapy for locally advanced hypopharyngeal cancer. ( Colpaert, C; Schrijvers, D; Van den Brande, J; Vermorken, JB, 1999)
"Thirteen patients with previously untreated squamous cell carcinoma of the hypopharynx, T3 or T4, were included."6.71Early response to chemotherapy in hypopharyngeal cancer: assessment with (11)C-methionine PET, correlation with morphologic response, and clinical outcome. ( Agostini, D; Babin, E; Bequignon, A; Chesnay, E; Constans, JM; Moreau, S; Regeasse, A; Sobrio, F, 2003)
" We conducted a retrospective study to evaluate the efficacy of this protocol with taxene, cisplatin and 5-fluorouracil in Chinese patients with hypopharyngeal cancer that chose preservation strategy."3.88Rational choice of induction chemotherapy-based larynx preservation for hypopharyngeal cancer. ( Bai, Y; Fang, J; Feng, L; Hou, L; Li, P; Lian, M; Liu, S; Ma, H; Meng, L; Zhong, Q, 2018)
"In order to make possible organ preservation, since 2007 our hospital has performed induction chemotherapy (ICT) with cisplatin and 5-fluorouracil (PF) for hypopharyngeal cancer as chemoselection, followed by alternating chemoradiotherapy (ACRT) with docetaxel, cisplatin, and 5-fluorouracil in (TPF) good responders and curative surgery was used in poor responders."3.83Chemoselection combined with alternating chemoradiotherapy or surgery for hypopharyngeal cancer. ( Ikeda, M; Imaizumi, M; Matsui, T; Matsuzuka, T; Nakaegawa, Y; Nomoto, M; Nomoto, Y; Omori, K; Saijoh, S; Sato, H; Suzuki, M; Suzuki, R; Suzuki, Y; Tada, Y; Tani, A, 2016)
"In head and neck cancer including hypopharyngeal cancer, cisplatin and 5-fluorouracil (5-FU) usually have been used as neoadjuvant chemotherapeutic agents."3.73Effects of cisplatin, 5-fluorouracil, and radiation on cell cycle regulation and apoptosis in the hypopharyngeal carcinoma cell line. ( An, WG; Chon, KM; Goh, EK; Kim, YS; Lee, BJ; Roh, HJ; Wang, SG, 2005)
"A 58-year-old man with hypopharyngeal cancer who developed 5-fluorouracil-induced leukoencephalopathy."3.73Reversible impairment of auditory callosal pathway in 5-fluorouracil-induced leukoencephalopathy: parallel changes in function and imaging. ( Fujimoto, C; Ito, K; Iwasaki, S; Nakao, K; Sugasawa, M, 2006)
"We present the case of a patient with a locally advanced hypopharyngeal carcinoma who developed a severe cytomegalovirus (CMV) colitis after his first chemotherapy course with 5-fluorouracil (5-FU), docetaxel and cisplatin."3.70Cytomegalovirus colitis after administration of docetaxel-5-fluorouracil-cisplatin chemotherapy for locally advanced hypopharyngeal cancer. ( Colpaert, C; Schrijvers, D; Van den Brande, J; Vermorken, JB, 1999)
"Acute Grade 3 (G3) dysphagia was higher in DL2 (87% DL2 vs."2.77Dose-escalated intensity-modulated radiotherapy is feasible and may improve locoregional control and laryngeal preservation in laryngo-hypopharyngeal cancers. ( A'hern, R; Barbachano, Y; Bhide, SA; Bidmead, AM; Clark, C; Guerrero-Urbano, MT; Harrington, KJ; Hickey, J; Miah, AB; Newbold, KL; Nicol, R; Nutting, CM; St Rose, S; Tanay, M, 2012)
"Objectives were to assess maximum tolerated dose, dose-limiting toxicity (DLT) and to recommend a safe dose of LAP when administered with 4 cycles of TPF followed by CRT."2.77EORTC 24051: unexpected side effects in a phase I study of TPF induction chemotherapy followed by chemoradiation with lapatinib, a dual EGFR/ErbB2 inhibitor, in patients with locally advanced resectable larynx and hypopharynx squamous cell carcinoma. ( Andry, G; Awada, A; Bogaerts, J; El-Hariry, I; Fortpied, C; Lacombe, D; Lalami, Y; Langendijk, JA; Liberatoscioli, C; Specenier, PM; Vermorken, JB, 2012)
"0 Gy/fraction) in combination with weekly cetuximab throughout radiotherapy."2.76Phase II study of induction chemotherapy with TPF followed by radioimmunotherapy with Cetuximab and intensity-modulated radiotherapy (IMRT) in combination with a carbon ion boost for locally advanced tumours of the oro-, hypopharynx and larynx--TPF-C-HIT. ( Debus, J; Desta, A; Habl, G; Jensen, AD; Krauss, J; Mavtratzas, A; Münter, MW; Potthoff, K; Windemuth-Kiesselbach, C, 2011)
"For patients with advanced laryngeal cancer, a trial was designed to determine if chemotherapy alone, in patients achieving a complete histologic complete response after a single neoadjuvant cycle, was an effective treatment with less morbidity than concurrent chemoradiotherapy."2.75Chemotherapy alone for organ preservation in advanced laryngeal cancer. ( Bradford, CR; Chepeha, DB; Divi, V; Eisbruch, A; Hogikyan, ND; Lee, JS; Moyer, JS; Prince, ME; Teknos, TN; Tsien, CI; Urba, SG; Wolf, GT; Worden, FP, 2010)
"Thirteen patients with previously untreated squamous cell carcinoma of the hypopharynx, T3 or T4, were included."2.71Early response to chemotherapy in hypopharyngeal cancer: assessment with (11)C-methionine PET, correlation with morphologic response, and clinical outcome. ( Agostini, D; Babin, E; Bequignon, A; Chesnay, E; Constans, JM; Moreau, S; Regeasse, A; Sobrio, F, 2003)
"Treatment with sodium selenite is well tolerated and easy to deliver."2.71Selenium in the treatment of radiation-associated secondary lymphedema. ( Bruns, F; Büntzel, J; DeVries, AF; Glatzel, M; Kisters, K; Micke, O; Mücke, R; Schäfer, U; Schönekaes, K, 2003)
"The histology was squamous cell carcinoma in 44 patients and adenocarcinoma in 3 patients with esophagus cancer."2.68Chemotherapy rapidly alternating with twice-a-day accelerated radiation therapy in carcinomas involving the hypopharynx or esophagus: an update. ( Beattie, E; Malamud, S; Nussbaum, M; Vikram, B; Yu, L; Yudelman, I, 1995)
"To analyze clinical and pharmacokinetic data of cisplatin (CP)/fluorouracil (FU)/l folinic acid (l FA) chemotherapy administered as first-line treatment to locally advanced head and neck cancer patients."2.68Phase II trial of cisplatin, fluorouracil, and pure folinic acid for locally advanced head and neck cancer: a pharmacokinetic and clinical survey. ( Dassonville, O; Demard, F; Etienne, MC; Guillot, T; Milano, G; Mobayen, H; Otto, J; Saudes, L; Schneider, M; Thyss, A, 1995)
"Hypopharyngeal cancer is a relatively rare malignancy with poor prognosis."1.72Biomarker discovery for practice of precision medicine in hypopharyngeal cancer: a theranostic study on response prediction of the key therapeutic agents. ( Eguchi, H; Grénman, R; Kawabata-Iwakawa, R; Kawata-Shimamura, Y; Nakahira, M; Nishiyama, M; Okazaki, Y; Sugasawa, M; Yoda, T, 2022)
"Head and neck squamous cell carcinomas (HNSCCs) are characterized by marked heterogeneity in their biological behavior and response to treatment."1.40p27 and BCL2 expression predicts response to chemotherapy in head and neck squamous cell carcinomas. ( Fresno, MF; García-Pedrero, JM; Hermsen, M; Moreno-Galindo, C; Rodrigo, JP; Suárez, C, 2014)
"Mucositis was the major acute toxicity, but this was well tolerated in most subjects."1.36Weekly low-dose docetaxel-based chemoradiotherapy for locally advanced oropharyngeal or hypopharyngeal carcinoma: a retrospective, single-institution study. ( Fujii, M; Fukada, J; Kawaguchi, O; Kubo, A; Kunieda, E; Ohashi, T; Shigematsu, N; Shiotani, A; Takeda, A; Tomita, T, 2010)
"Patients receiving C-IMRT for head-and-neck cancer had repeat CT scans at weeks 2, 3, 4, and 5 during radiotherapy."1.36Weekly volume and dosimetric changes during chemoradiotherapy with intensity-modulated radiation therapy for head and neck cancer: a prospective observational study. ( Barbachano, Y; Bhide, SA; Burke, K; Davies, M; El-Hariry, IA; Hansen, V; Harrington, KJ; McNair, HA; Newbold, K; Nutting, CM, 2010)
"Patients presenting with squamous cell carcinoma of the pyriform sinus, epilarynx or postcricoid area with indication of pharyngolaryngectomy, without previous treatment, distant metastasis, multiple primaries or general contraindications for surgery and chemotherapy were included in the study."1.29[Perioperative chemotherapy of squamous cell carcinoma of the hypopharynx]. ( Domenge, C; Eschwège, F; Leridant, AM; Luboinski, B; Mamelle, G; Wibault, P, 1996)
"Average survival for advanced head and neck cancer (AHNC) is 18 months."1.27Pretreatment with chemotherapy in patients with advanced head and neck cancer. ( Barron, P; Cripps, C; Danjoux, C; de la Bastide, Y; Hardie, J; Nichol, J; Odell, P, 1985)
"Fifty-seven patients with advanced squamous carcinoma of the larynx and hypopharynx were entered on a pilot study of initial therapy using split course radiation therapy combined with simultaneous chemotherapy using mitomycin-C and 5-fluorouracil."1.27A pilot study of mitomycin-C/5-fluorouracil infusion combined with split course radiation therapy for carcinomas of the larynx and hypopharynx. ( Beale, FA; Cummings, BJ; Elhakim, T; Harwood, AR; Keane, TJ; Payne, DG; Rawlinson, E, 1986)
"One hundred and eight patients with squamous cell carcinoma of the upper aerodigestive tract (UADT) (T3, T4, NO-N3; 17% stage II, 54% stage III, 27% stage IV) were given three courses of chemotherapy before any local treatment."1.27Induction chemotherapy with cis-platinum and 5-fluorouracil for squamous cell carcinoma of the head and neck. ( Caldani, C; Chauvel, P; Demard, F; Santini, J; Schneider, M; Thyss, A; Vallicioni, J, 1986)
"The treatment of 192 patients with cancer of the larynx, 60 patients with hypopharyngeal and cervical esophageal cancer, and 23 patients with epipharyngeal cancer with FAR therapy during 6 years from 1972 to 1977 resulted in highly effective synergism, and the improved points of this therapy were considered."1.27Synergistic combination therapy of 5-fluorouracil, vitamin A, and cobalt-60 radiation for head and neck tumors--antitumor combination therapy with vitamin A. ( Komiyama, S; Kudoh, S; Kuwano, M; Yanagita, T, 1985)

Research

Studies (111)

TimeframeStudies, this research(%)All Research%
pre-19905 (4.50)18.7374
1990's23 (20.72)18.2507
2000's42 (37.84)29.6817
2010's37 (33.33)24.3611
2020's4 (3.60)2.80

Authors

AuthorsStudies
Kawata-Shimamura, Y1
Eguchi, H1
Kawabata-Iwakawa, R1
Nakahira, M1
Okazaki, Y1
Yoda, T1
Grénman, R1
Sugasawa, M2
Nishiyama, M1
Hitt, R1
Iglesias, L1
López-Pousa, A1
Berrocal-Jaime, A1
Grau, JJ1
García-Girón, C1
Martínez-Trufero, J1
Guix, M1
Lambea-Sorrosal, J1
Del Barco-Morillo, E1
León-Vintró, X1
Cunquero-Tomas, AJ1
Baste, N1
Ocaña, A1
Cruz-Hernández, JJ1
Sahashi, Y1
Nawa, T1
Echanique, KA1
Evans, LK1
Han, AY1
Chhetri, DK1
St John, MA1
Hess, AK1
Müer, A1
Mairinger, FD1
Weichert, W1
Stenzinger, A1
Hummel, M1
Budach, V4
Tinhofer, I1
Zhong, Q2
Fang, J2
Huang, Z1
Yang, Y1
Lian, M2
Liu, H1
Zhang, Y1
Ye, J1
Hui, X1
Wang, Y1
Ying, Y1
Zhang, Q2
Cheng, Y1
Dietz, A5
Wichmann, G1
Kuhnt, T1
Pfreundner, L2
Hagen, R2
Scheich, M1
Kölbl, O1
Hautmann, MG1
Strutz, J1
Schreiber, F1
Bockmühl, U1
Schilling, V1
Feyer, P1
de Wit, M1
Maschmeyer, G1
Jungehülsing, M1
Schroeder, U2
Wollenberg, B1
Sittel, C1
Münter, M1
Lenarz, T1
Klussmann, JP1
Guntinas-Lichius, O2
Rudack, C1
Eich, HT2
Foerg, T1
Preyer, S1
Westhofen, M2
Welkoborsky, HJ2
Esser, D1
Thurnher, D1
Remmert, S1
Sudhoff, H1
Görner, M1
Bünzel, J1
Held, S1
Knödler, M1
Lordick, F1
Wiegand, S1
Vogel, K1
Boehm, A1
Flentje, M4
Keilholz, U2
Liu, S1
Ma, H1
Meng, L1
Bai, Y1
Feng, L1
Li, P1
Hou, L1
Sun, W1
Chen, L1
Huang, JQ1
Li, J1
Zhu, XL1
Wen, YH1
Wen, WP1
Suzuki, K1
Hayashi, R3
Ebihara, M1
Miyazaki, M2
Shinozaki, T1
Daiko, H1
Sakuraba, M2
Zenda, S2
Tahara, M3
Fujii, S1
Moreno-Galindo, C1
Hermsen, M1
García-Pedrero, JM1
Fresno, MF1
Suárez, C1
Rodrigo, JP1
Maggiore, RJ1
Curran, EK1
Witt, ME1
Haraf, DJ1
Vokes, EE1
Cohen, EE1
Sato, K2
Kubota, A1
Furukawa, M1
Kitani, Y1
Nakayama, Y1
Nonaka, T1
Mizoguchi, N1
Shiomi, M1
Zhang, X1
Wang, J1
Wu, W1
Ma, L1
Liu, M1
Zhao, F1
Huang, D1
Stromberger, C1
Poettgen, C1
Baumann, M1
Budach, W1
Grabenbauer, G1
Marnitz, S1
Olze, H1
Wernecke, KD1
Ghadjar, P1
Yoon, TM1
Kim, SA1
Lee, DH1
Lee, JK3
Park, YL1
Lee, KH1
Chung, IJ1
Joo, YE1
Lim, SC2
Bozec, A1
Benezery, K2
Chamorey, E3
Ettaiche, M1
Vandersteen, C1
Dassonville, O4
Poissonnet, G3
Riss, JC1
Hannoun-Lévi, JM1
Chand, ME1
Leysalle, A1
Saada, E1
Sudaka, A1
Haudebourg, J1
Hebert, C1
Falewee, MN1
Demard, F7
Santini, J4
Peyrade, F2
Matsuzuka, T1
Sato, H1
Suzuki, R1
Suzuki, M1
Saijoh, S1
Ikeda, M2
Nakaegawa, Y1
Tani, A1
Imaizumi, M1
Matsui, T1
Nomoto, Y1
Nomoto, M1
Tada, Y1
Suzuki, Y1
Omori, K1
Janoray, G1
Pointreau, Y2
Garaud, P2
Chapet, S2
Alfonsi, M2
Sire, C2
Jadaud, E1
Calais, G3
Yanagi, T1
Shibamoto, Y1
Ogino, H1
Baba, F1
Murai, T1
Nagai, A1
Miyakawa, A1
Sugie, C1
Li, L1
Tan, F1
Yue, W1
Wang, H2
Xue, H1
Wen, Z1
Henriques De Figueiredo, B1
Fortpied, C2
Menis, J1
Lefebvre, JL3
Barzan, L1
de Raucourt, D1
Geoffrois, L1
Giurgea, L1
Hupperets, P1
Leemans, CR1
Licitra, L2
Rolland, F1
Tesselaar, M1
Vermorken, JB3
Grégoire, V1
Bossi, P1
Bergamini, C1
Miceli, R1
Cova, A1
Orlandi, E1
Resteghini, C1
Locati, L1
Alfieri, S1
Imbimbo, M1
Granata, R1
Mariani, L1
Iacovelli, NA1
Huber, V1
Cavallo, A1
Rivoltini, L1
Nakashima, T3
Yasumatsu, R2
Asai, K1
Uryu, H1
Kogo, R1
Nakagawa, T2
Sakaguchi, M1
Maebayashi, T1
Aizawa, T1
Ishibashi, N1
Saito, T2
Otsuki, N1
Masai, Y1
Sasaki, R1
Tsukuda, M3
Nibu, K1
Tai, SK1
Yang, MH1
Wang, LW1
Tsai, TL1
Chu, PY1
Wang, YF1
Huang, JL1
Chang, SY1
Rodriguez, CP1
Adelstein, DJ2
Rybicki, LA1
Saxton, JP1
Lorenz, RR1
Wood, BG1
Strome, M1
Esclamado, RM1
Lavertu, P1
Carroll, MA1
Forastiere, AA1
Trotti, AM1
Posner, MR1
Norris, CM1
Wirth, LJ1
Shin, DM1
Cullen, KJ1
Winquist, EW1
Blajman, CR1
Mickiewicz, EA1
Frenette, GP1
Plinar, LF1
Cohen, RB1
Steinbrenner, LM1
Freue, JM1
Gorbunova, VA1
Tjulandin, SA1
Raez, LE1
Adkins, DR1
Tishler, RB1
Roessner, MR1
Haddad, RI1
Tuchais, C1
Tortochaux, J2
Faivre, S1
Guerrif, S1
Fukada, J1
Shigematsu, N1
Takeda, A1
Ohashi, T1
Tomita, T1
Shiotani, A1
Kunieda, E1
Kawaguchi, O1
Fujii, M1
Kubo, A1
Prades, JM2
Lallemant, B1
Garrel, R1
Reyt, E1
Righini, C1
Schmitt, T1
Remini, N1
Saban-Roche, L1
Timoshenko, AP2
Trombert, B1
Guerrier, B1
Matsutani, T1
Sasajima, K1
Kobayashi, Y1
Suzuki, S2
Maruyama, H1
Miyamoto, M1
Yokoyama, T1
Sugiura, A1
Matsushita, A1
Yanagi, K1
Matsuda, A2
Arai, H1
Nishi, Y1
Wakabayashi, H1
Tajiri, T1
Kogashiwa, Y1
Yamauchi, K1
Nagafuji, H1
Matsuda, T1
Tsubosaka, T1
Tsutsumi, T1
Karaho, T1
Kohno, N1
Divi, V1
Worden, FP1
Prince, ME1
Eisbruch, A2
Lee, JS1
Bradford, CR2
Chepeha, DB1
Teknos, TN1
Hogikyan, ND1
Moyer, JS1
Tsien, CI1
Urba, SG3
Wolf, GT2
Liu, WS1
Hsin, CH1
Chou, YH1
Liu, JT1
Wu, MF1
Tseng, SW1
Tseng, HC1
Wang, TH1
Su, MC1
Lee, H1
Bhide, SA2
Davies, M1
Burke, K1
McNair, HA1
Hansen, V1
Barbachano, Y2
El-Hariry, IA1
Newbold, K1
Harrington, KJ2
Nutting, CM2
Huang, WY1
Jen, YM1
Chen, CM1
Su, YF1
Lin, CS1
Lin, YS1
Chang, YN1
Chao, HL1
Lin, KT1
Chang, LP1
Yang, L1
Chen, WK1
Guo, ZM1
Gu, MF1
Huang, HQ1
Yang, AK1
Habl, G2
Jensen, AD2
Potthoff, K2
Uhl, M1
Hof, H1
Hajda, J1
Simon, C1
Debus, J2
Krempien, R1
Münter, MW2
Okumura, Y1
Ryotokuji, T1
Miura, A1
Kato, T1
Tomemori, T1
Mitsuhashi, T1
Monma, K1
Izumi, Y1
Miah, AB1
Guerrero-Urbano, MT1
Clark, C1
Bidmead, AM1
St Rose, S1
A'hern, R1
Tanay, M1
Hickey, J1
Nicol, R1
Newbold, KL1
Krauss, J1
Desta, A1
Mavtratzas, A1
Windemuth-Kiesselbach, C1
Kawashima, M2
Arahira, S2
Ogino, T2
Chitose, S1
Chijiwa, H1
Maeda, A1
Umeno, H1
Kiyokawa, K1
Hayabuchi, N1
Fujita, H1
Tomita, M1
Matsuyama, H1
Yamazaki, K1
Takahashi, S1
Lalami, Y1
Specenier, PM1
Awada, A1
Lacombe, D1
Liberatoscioli, C1
El-Hariry, I1
Bogaerts, J1
Andry, G1
Langendijk, JA1
Furusaka, T1
Tanaka, A1
Matsuda, H2
Watanabe, A1
Taniguchi, M1
Kawabori, S1
Chesnay, E1
Babin, E1
Constans, JM1
Agostini, D1
Bequignon, A1
Regeasse, A1
Sobrio, F1
Moreau, S1
Micke, O1
Bruns, F1
Mücke, R1
Schäfer, U1
Glatzel, M1
DeVries, AF1
Schönekaes, K1
Kisters, K1
Büntzel, J1
Schmidberger, H1
Rave-Fränk, M1
Kim, S1
Hille, A1
Pradier, O1
Hess, CF1
Miyahara, H1
Nario, K1
Matsushiro, N1
Sasai, H1
Kajikawa, H1
Rudat, V3
Hoppe, F1
Kuratomi, Y2
Yamamoto, T1
Kumamoto, Y1
Masuda, M1
Koike, K1
Komiyama, S3
Altundag, O1
Gullu, I1
Altundag, K1
Yalcin, S1
Ozyar, E1
Cengiz, M1
Akyol, F1
Yucel, T1
Hosal, S1
Sozeri, B1
Moon, J1
Giri, PG1
Hanna, E1
Yoo, GH1
Leblanc, M1
Ensley, JF1
Schuller, DE1
Bourhis, J1
Temam, S1
Lusinchi, A1
Janot, F1
Wibault, P3
Pignon, JP1
Chan, L1
Yeo, W1
Leung, SF1
Griffith, J1
Ng, EK1
Chan, AT1
Lee, BJ1
Chon, KM1
Kim, YS1
An, WG1
Roh, HJ1
Goh, EK1
Wang, SG1
Yom, SS1
Machtay, M1
Biel, MA1
Sinard, RJ1
El-Naggar, AK1
Weber, RS1
Rosenthal, DI1
Puri, DR1
Chou, W1
Lee, N1
Endo, S1
Tsuji, K1
Nomura, Y1
Noguchi, Y1
Kida, A1
Tanaka, Y1
Bensadoun, RJ3
Magné, N2
Ramaïoli, A1
Lemanski, C1
Bourdin, S3
Marcy, PY3
Vallicioni, J3
Seng, H1
Alzieu, C1
Géry, B1
Chauvel, P3
Schneider, M5
Semrau, R1
Mueller, RP2
Stuetzer, H2
Staar, S2
Kocher, M1
Volling, P2
Schroeder, M2
Eckel, HE2
Fujimoto, C1
Ito, K2
Iwasaki, S1
Nakao, K1
Yip, KW1
Ito, E1
Mao, X1
Au, PY1
Hedley, DW1
Mocanu, JD1
Bastianutto, C1
Schimmer, A1
Liu, FF1
Lee, NY1
O'Meara, W1
Chan, K1
Della-Bianca, C1
Mechalakos, JG1
Zhung, J1
Wolden, SL1
Narayana, A1
Kraus, D1
Shah, JP1
Pfister, DG1
Nishimura, G2
Horiuchi, C1
Satake, K1
Yoshida, T1
Nagao, J1
Kawakami, M1
Kondo, N1
Arai, Y1
Taguchi, T1
Mikami, Y1
Fujii, H1
Nasu, K1
Lee, MS1
Ho, HC1
Hsiao, SH1
Hwang, JH1
Lee, CC1
Hung, SK1
Wadasaki, K1
Matsuura, K1
Murakami, Y1
Kenjo, M1
Kaneyasu, Y1
Fujita, M1
Tatsukawa, R1
Takeno, Y1
Hirakawa, K1
Werner, J1
Iro, H2
Yoon, MS1
Chung, WK1
Ahn, SJ1
Nam, TK1
Nah, BS1
Song, JY1
Yu, L1
Vikram, B2
Malamud, S1
Yudelman, I1
Nussbaum, M1
Beattie, E1
Etienne, MC2
Milano, G2
Thyss, A3
Otto, J1
Mobayen, H1
Saudes, L1
Guillot, T1
Reisser, C1
Haberkorn, U2
Dimitrakopoulou-Strauss, A1
Seifert, E2
Strauss, LG2
Thomas, C1
Koh, WJ1
Keane, TJ2
Cummings, BJ2
O'Sullivan, B1
Payne, D1
Rawlinson, E2
MacKenzie, R1
Danjoux, C2
Hodson, I1
Gedouin, D1
Desprez, P1
Perron, JJ1
Fleury, F1
Leclech, G1
Miglianico, L1
Belpomme, D1
Chenal, C1
Mamelle, G1
Domenge, C1
Eschwège, F1
Leridant, AM1
Luboinski, B2
de Crevoisier, R1
Mazeron, JJ1
Kievit, E1
Pinedo, HM1
Schlüper, HM1
Haisma, HJ1
Boven, E1
Beauvillain, C1
Mahé, M1
Peuvrel, P1
Bergerot, P1
Rivière, A1
Vignoud, J1
Deraucourt, D1
Wesoluch, M1
Schrader, M1
Schipper, J1
Jahnke, K1
Stuschke, M1
Sack, H1
Yamaoka, H1
Mochimatsu, I1
Nagahara, T1
Enomoto, H1
Kagata, H1
Kagesato, Y1
Daicho, S1
Mizuno, H1
Baba, Y1
Kawakami, K1
Julieron, M1
Germain, MA1
Schwaab, G1
Marandas, P1
Bourgain, JL1
Pivot, X2
Prevost, B1
Coche-Dequeant, B1
Courdi, A1
Teissier, E1
Lagrange, JL1
Van den Brande, J1
Schrijvers, D1
Colpaert, C1
Thornton, AF1
Terrell, JE1
Carpenter, V1
Miller, T1
Tang, G1
Strawderman, M1
Lorenz, M1
Regele, H1
Kovarik, J1
Hörl, WH1
Klauser, R1
Guardiola, E1
Amin, R1
Akisada, T1
Harada, T1
Takemoto, T1
Fukuda, K1
Morita, N1
Aihara, T1
Kajihara, Y1
Imai, S1
Gyoten, M1
Imajo, Y1
Hiratsuka, J1
Schmitt, TM1
Simon, PG1
de Cornulier, J1
Durand, M1
Guillot, A1
Martin, C1
Sarini, J1
Bocciolini, C1
Fournier, C1
Penel, N1
Kara, A1
Van, JT1
Bauer, FP1
Schadel, A1
Bleier, R1
Wissen-Siegert, I1
Karp, DD1
Vaughan, CW1
Carter, R1
Willett, B1
Heeren, T1
Calarese, P1
Zeitels, S1
Strong, MS1
Hong, WK1
Masuda, A1
Tomita, K1
Zingu, K1
Fietkau, R1
Grabenbauer, GG1
Altendorf-Hofmann, A1
Sauer, R1
Laccourreye, H1
Bassot, V1
Lacau St Guily, J1
Brasnu, D1
Menard, M1
Donnadieu, S1
Jacquillat, C1
Cripps, C1
Odell, P1
Nichol, J1
de la Bastide, Y1
Barron, P1
Hardie, J1
Harwood, AR1
Beale, FA1
Payne, DG1
Elhakim, T1
Caldani, C1
Kudoh, S1
Yanagita, T1
Kuwano, M1

Clinical Trials (13)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Randomized Phase III Trial Comparing Induction Chemotherapy With Cisplatin/5-fluorouracil (PF) or Docetaxel/Cisplatin/5-fluorouracil (TPF) Plus Chemoradiotherapy (CRT) Versus CRT Alone as First-line Treatment or Unresectable Locally Advanced Head and Neck[NCT00261703]Phase 2/Phase 3439 participants (Actual)Interventional2002-12-31Completed
Randomised Phase II Screening Study to be Used in an TP/TPF-chemotherapy (Short Induction) Before TP/TPF-induction, Radiotherapy With or Without Cetuximab in the Primary Therapy of the Only by Laryngectomy Operable Carcinoma of the Larynx/Hypopharynx[NCT00508664]Phase 2180 participants (Actual)Interventional2007-07-31Completed
ELOS - Induction Chemotherapy With Docetaxel and Cisplatin Followed by Radiation Compared to Additional PD-1 Inhibition in CPS ≥1 Advanced Laryngeal/Hypopharyngeal Cancer Suitable for Laryngectomy Selected After Early Response Evaluation[NCT06137378]Phase 2140 participants (Anticipated)Interventional2024-11-30Not yet recruiting
Induction Chemotherapy and Toripalimab Followed by Surgery or Radiotherapy for Larynx Preservation in Resectable Laryngeal/Hypopharyngeal Carcinoma[NCT04995120]Phase 242 participants (Anticipated)Interventional2021-04-07Recruiting
Microbiota, Inflammatory Environment, Clinical and Radiomic Features as Predictors of Normal Tissue Response in Radiotherapy for Prostate and Head-and-neck Cancer[NCT03294122]400 participants (Anticipated)Observational2017-02-02Recruiting
New Strategy of Improving Treatment Outcome and Larynx-preservation Rate in Locally Advanced Hypopharyngeal Carcinoma[NCT03558035]Phase 296 participants (Anticipated)Interventional2014-09-30Recruiting
Phase I/II Study on Induction Chemotherapy Followed by Chemoradiation With or Without Lapatinib, a Dual EGFR/ErbB2 Kinase Inhibitor, in Patients With Locally Advanced Larynx and Hypopharynx Squamous Cell Carcinoma[NCT00498953]Phase 1/Phase 27 participants (Actual)Interventional2007-05-31Completed
The Role of Sodium Selenite Supplementation in Patients With Locally Advanced Head and Neck Cancer Undergoing Concurrent Chemoradiotherapy[NCT05451576]60 participants (Anticipated)Interventional2020-08-12Recruiting
Induction Chemotherapy Followed By Chemoradiation For Organ Preservation In Patients With Advanced Resectable Cancer Of The Hypopharynx And Base Of Tongue, Phase II[NCT00002735]Phase 268 participants (Actual)Interventional1996-04-30Terminated (stopped due to Terminated due to poor accrual.)
Phase III Randomized Study of Radiotherapy With or Without Cisplatin and Fluorouracil for Locally Advanced, Nonresectable Squamous Cell Cancer of the Oropharynx or Hypopharynx[NCT00003627]Phase 3160 participants (Anticipated)Interventional1998-10-31Completed
Radiosensitization With a COX-2 Inhibitor (Celecoxib), With Chemoradiation for Cancer of the Head and Neck[NCT00581971]Phase 1/Phase 230 participants (Actual)Interventional2002-09-30Completed
Quarterback 22: A Phase II Clinical Trial of Sequential Therapy and De-Intensified Chemoradiotherapy for Locally Advanced HPV Positive Oropharynx Cancer[NCT02945631]43 participants (Actual)Interventional2016-04-25Active, not recruiting
The Quarterback Trial: A Randomized Phase III Clinical Trial Comparing Reduced and Standard Radiation Therapy Doses for Locally Advanced HPV Positive Oropharynx Cancer[NCT01706939]Phase 323 participants (Actual)Interventional2012-09-01Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Response as Evaluated by Recurrence of Diseases

Evaluate the response to concurrent celecoxib, carboplatin, paclitaxel, and radiotherapy in the treatment of locally advanced SSC of the head and neck. Response is determined by local control only, local and distant metastasis, distant metastasis only, second primary, and surgical salvage. (NCT00581971)
Timeframe: 2 years from end of treatment (Radiation therapy)

InterventionParticipants (Number)
Local Control OnlyLocal Control and Distant MetastasisDistant Metastatsis OnlySecondary Primary - Site UnknownSurgical Salvage
Recurrence62123

Toxicity of Celecoxib With Concurrent Weekly Chemotherapy and Radiotherapy in the Treatment of Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck.

Particpants experiencing Acute Toxicities > Grade 3 (NCT00581971)
Timeframe: 2 years from radiation therapy

Interventionparticipants (Number)
HematologicDermatitisMucositis/Dysphagia
Acute Toxicity12716

Biomarkers Predictive of Failure

To determine biomarkers predictive of failure with either reduced or standard dose radiotherapy. (NCT01706939)
Timeframe: at 5 years

Interventionbiomarkers (Number)
Reduced Dose Radiation0
Standard Dose Radiation0

Change in MD Anderson Dysphagia Inventory (MDADI) From Baseline

MDADI is a questionnaire of 20 questions and contains a global subscale, and three other categories of questions (emotional, functional, and physical). The scores are summed and a mean score is calculated. This mean score was multiplied by 20 to obtain a score, with a range of 0 (extremely low functioning) to 100 (high functioning). Thus, a higher MDADI score represented better day-to-day functioning and better QOL. (NCT01706939)
Timeframe: Baseline and 5 years

Interventionscore on a scale (Mean)
Reduced Dose Radiation-8.12
Standard Dose Radiation-8.93

Change in Xerostomia Questionnaire (XQ)

XQ is a nine questions survey developed specifically for xerostomia symptoms. The scores are summed and a mean score is calculated on a scale of 0 (low xerostomia interference) to 10 (high xerostomia interference). A lower or negative score reflects a better quality of life compared to baseline. (NCT01706939)
Timeframe: Baseline and 5 years

Interventionscore on a scale (Mean)
Reduced Dose Radiation2.18
Standard Dose Radiation4.38

Number of Participants With Acute Toxicity of Chemoradiotherapy (CRT)

Number of participants with acute toxicity treated with reduced or standard dose CRT. (NCT01706939)
Timeframe: at 5 years

InterventionParticipants (Count of Participants)
Reduced Dose Radiation3
Standard Dose Radiation1

Number of Participants With Local-regional Control

Local-regional control (LRC) at 3 years in patients with advanced HPV related oropharynx cancer or unknown primary treated with reduced or standard dose radiation. (NCT01706939)
Timeframe: at 3 years

InterventionParticipants (Count of Participants)
Reduced Dose Radiation10
Standard Dose Radiation7

Number of Participants With Overall Survival at 5 Years

Overall Survival (OS) 5 years treated with reduced or standard dose CRT. (NCT01706939)
Timeframe: at 5 years

InterventionParticipants (Count of Participants)
Reduced Dose Radiation10
Standard Dose Radiation7

Change in European Organization for Research and Treatment of Cancer Questionnaire for Head and Neck (EORTC HN)

The EORTC Head and Neck module was specifically designed and validated for head and neck cancer patients. This 35-item questionnaire contains 7 symptom scales (pain, swallowing, senses, speech, social eating, social contact, and sexuality), 6 single-item scales (difficulties of teeth, mouth opening, dry mouth, sticky saliva, coughing, and feeling ill), and 5 items about the additional use of pain medicine, nutritional supplements, and feeding tube and changes in body weight. All items were transformed to scales from 0 to 100, and divided into respective sub-scores of global health (GHS), functional (FS), and symptom scale (SS). Subscales from 0-100. A high score on global health and functional scale represents a better level of functioning, whereas a high score on a symptom scale and head and neck module indicates more severe symptoms. (NCT01706939)
Timeframe: Baseline and 5 years

,
Interventionscore on a scale (Mean)
EORTC GHSEORTC FSEORTC SSEORTC HN
Reduced Dose Radiation5.955.14-3.91-2.80
Standard Dose Radiation-30.56-6.3314.978.97

Change in MD Anderson Symptom Inventory Symptom Inventory and Severity (MDASI-HN SI and SS)

"MD Anderson Symptom Inventory Symptom Inventory and Severity (MDASI-HN SI and SS) MDASI Head and Neck is a site-specific MDASI module which includes the core MDASI 13 symptom severity items (SS) and 6 symptom interference items (SI), alongside 9 items relevant to head and neck cancer. The scores are summed and a mean score is calculated on a scale of 0 (low severity or interference) to 10 (high severity or complete interference). In order to calculate the mean score, a majority of the subscale's items must have been completed.~A lower or negative score reflects a better quality of life compared to baseline." (NCT01706939)
Timeframe: Baseline and 5 years

,
Interventionscore on a scale (Mean)
MDASI-HN SIMDASI-HN SS
Reduced Dose Radiation0.640.52
Standard Dose Radiation1.561.48

Number of Participants With Progression Free Survival (PFS)

Progression free survival (PFS) at 5 years in patients with advanced HPV related oropharynx cancer, nasopharynx cancer or unknown primary treated with reduced or standard dose radiation. (NCT01706939)
Timeframe: at 3 and 5 years

,
InterventionParticipants (Count of Participants)
at 3 yearsat 5 years
Reduced Dose Radiation1010
Standard Dose Radiation77

Reviews

6 reviews available for fluorouracil and Hypopharyngeal Cancer

ArticleYear
Cancer of the Larynx and Hypopharynx.
    Hematology/oncology clinics of North America, 2021, Volume: 35, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fluorouracil; H

2021
Approaches to preserve larynx function in locally advanced laryngeal and hypopharyngeal cancer.
    Onkologie, 2004, Volume: 27, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fluorouracil; Humans; Hyp

2004
[Larynx preservation: nonsurgical approaches].
    Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2004, Volume: 8 Suppl 1

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco

2004
[Current role for induction chemotherapy in head and neck tumors].
    Laryngo- rhino- otologie, 2008, Volume: 87, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali

2008
[Update on cancerology of the upper aerodigestive tract].
    Bulletin du cancer, 1998, Volume: 85, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Transplantation; Clinical Tr

1998
Sustained complete remission of stage IV carcinoma of the pyriform fossa following chemotherapy.
    The Journal of laryngology and otology, 2002, Volume: 116, Issue:2

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C

2002

Trials

33 trials available for fluorouracil and Hypopharyngeal Cancer

ArticleYear
MiR-200b and miR-155 as predictive biomarkers for the efficacy of chemoradiation in locally advanced head and neck squamous cell carcinoma.
    European journal of cancer (Oxford, England : 1990), 2017, Volume: 77

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemoradiotherapy; C

2017
A response prediction model for taxane, cisplatin, and 5-fluorouracil chemotherapy in hypopharyngeal carcinoma.
    Scientific reports, 2018, 08-23, Volume: 8, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Bridged-Ring Compounds; Cisplatin; Female; Fluorouracil; Head an

2018
Induction chemotherapy (IC) followed by radiotherapy (RT) versus cetuximab plus IC and RT in advanced laryngeal/hypopharyngeal cancer resectable only by total laryngectomy-final results of the larynx organ preservation trial DeLOS-II.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2018, 10-01, Volume: 29, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Chemoradiotherapy; Cisplatin

2018
Induction chemotherapy (IC) followed by radiotherapy (RT) versus cetuximab plus IC and RT in advanced laryngeal/hypopharyngeal cancer resectable only by total laryngectomy-final results of the larynx organ preservation trial DeLOS-II.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2018, 10-01, Volume: 29, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Chemoradiotherapy; Cisplatin

2018
Induction chemotherapy (IC) followed by radiotherapy (RT) versus cetuximab plus IC and RT in advanced laryngeal/hypopharyngeal cancer resectable only by total laryngectomy-final results of the larynx organ preservation trial DeLOS-II.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2018, 10-01, Volume: 29, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Chemoradiotherapy; Cisplatin

2018
Induction chemotherapy (IC) followed by radiotherapy (RT) versus cetuximab plus IC and RT in advanced laryngeal/hypopharyngeal cancer resectable only by total laryngectomy-final results of the larynx organ preservation trial DeLOS-II.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2018, 10-01, Volume: 29, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Chemoradiotherapy; Cisplatin

2018
Hyperfractionated accelerated radiation therapy (HART) of 70.6 Gy with concurrent 5-FU/Mitomycin C is superior to HART of 77.6 Gy alone in locally advanced head and neck cancer: long-term results of the ARO 95-06 randomized phase III trial.
    International journal of radiation oncology, biology, physics, 2015, Apr-01, Volume: 91, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe

2015
Long-term Results of a Multicenter Randomized Phase III Trial of Induction Chemotherapy With Cisplatin, 5-fluorouracil, ± Docetaxel for Larynx Preservation.
    Journal of the National Cancer Institute, 2016, Volume: 108, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy,

2016
Long-term update of the 24954 EORTC phase III trial on larynx preservation.
    European journal of cancer (Oxford, England : 1990), 2016, Volume: 65

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe

2016
Single-cycle induction chemotherapy for resectable advanced hypopharyngeal cancer.
    International journal of clinical oncology, 2017, Volume: 22, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel; Femal

2017
Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Volume: 20, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous

2009
Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation.
    Journal of the National Cancer Institute, 2009, Apr-01, Volume: 101, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy,

2009
Randomized phase III trial comparing induction chemotherapy followed by radiotherapy to concomitant chemoradiotherapy for laryngeal preservation in T3M0 pyriform sinus carcinoma.
    Acta oto-laryngologica, 2010, Volume: 130, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cause of Death; Cisplatin;

2010
Concurrent chemoradiotherapy for organ function preservation in advanced patients with hypopharyngeal and laryngeal cancer.
    Oncology reports, 2009, Volume: 22, Issue:5

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C

2009
Chemotherapy alone for organ preservation in advanced laryngeal cancer.
    Head & neck, 2010, Volume: 32, Issue:8

    Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Combined Modal

2010
Treatment of locally advanced carcinomas of head and neck with intensity-modulated radiation therapy (IMRT) in combination with cetuximab and chemotherapy: the REACH protocol.
    BMC cancer, 2010, Nov-26, Volume: 10

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2010
Dose-escalated intensity-modulated radiotherapy is feasible and may improve locoregional control and laryngeal preservation in laryngo-hypopharyngeal cancers.
    International journal of radiation oncology, biology, physics, 2012, Feb-01, Volume: 82, Issue:2

    Topics: Adult; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell;

2012
Phase II study of induction chemotherapy with TPF followed by radioimmunotherapy with Cetuximab and intensity-modulated radiotherapy (IMRT) in combination with a carbon ion boost for locally advanced tumours of the oro-, hypopharynx and larynx--TPF-C-HIT.
    BMC cancer, 2011, May-19, Volume: 11

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2011
Prospective trial of chemotherapy-enhanced accelerated radiotherapy for larynx preservation in patients with intermediate-volume hypopharyngeal cancer.
    Head & neck, 2012, Volume: 34, Issue:10

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Squamous Cell; Chem

2012
EORTC 24051: unexpected side effects in a phase I study of TPF induction chemotherapy followed by chemoradiation with lapatinib, a dual EGFR/ErbB2 inhibitor, in patients with locally advanced resectable larynx and hypopharynx squamous cell carcinoma.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2012, Volume: 105, Issue:2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Che

2012
Early response to chemotherapy in hypopharyngeal cancer: assessment with (11)C-methionine PET, correlation with morphologic response, and clinical outcome.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2003, Volume: 44, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Female; F

2003
Selenium in the treatment of radiation-associated secondary lymphedema.
    International journal of radiation oncology, biology, physics, 2003, May-01, Volume: 56, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ci

2003
Induction chemotherapy with cisplatin and 5-fluorouracil followed by chemoradiotherapy or radiotherapy alone in the treatment of locoregionally advanced resectable cancers of the larynx and hypopharynx: results of single-center study of 45 patients.
    Head & neck, 2005, Volume: 27, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di

2005
Organ preservation for advanced resectable cancer of the base of tongue and hypopharynx: a Southwest Oncology Group Trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Jan-01, Volume: 23, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined

2005
French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: Results at 2 years (FNCLCC-GORTEC).
    International journal of radiation oncology, biology, physics, 2006, Mar-15, Volume: 64, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co

2006
Efficacy of intensified hyperfractionated and accelerated radiotherapy and concurrent chemotherapy with carboplatin and 5-fluorouracil: updated results of a randomized multicentric trial in advanced head-and-neck cancer.
    International journal of radiation oncology, biology, physics, 2006, Apr-01, Volume: 64, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy;

2006
Chemotherapy rapidly alternating with twice-a-day accelerated radiation therapy in carcinomas involving the hypopharynx or esophagus: an update.
    Cancer investigation, 1995, Volume: 13, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

1995
Phase II trial of cisplatin, fluorouracil, and pure folinic acid for locally advanced head and neck cancer: a pharmacokinetic and clinical survey.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe

1995
A randomized trial of radiation therapy compared to split course radiation therapy combined with mitomycin C and 5 fluorouracil as initial treatment for advanced laryngeal and hypopharyngeal squamous carcinoma.
    International journal of radiation oncology, biology, physics, 1993, Mar-15, Volume: 25, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy;

1993
[Cancers of the base of the tongue and hypopharynx: results of a multicenter randomized trial of chemotherapy prior to locoregional treatment].
    Bulletin du cancer. Radiotherapie : journal de la Societe francaise du cancer : organe de la societe francaise de radiotherapie oncologique, 1996, Volume: 83, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Female; Fluoro

1996
[Apropos of two recently published randomized trials of induction chemotherapy in nasopharyngeal and piriform sinus carcinoma].
    Bulletin du cancer. Radiotherapie : journal de la Societe francaise du cancer : organe de la societe francaise de radiotherapie oncologique, 1996, Volume: 83, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Cisplatin; Comb

1996
Final results of a randomized trial comparing chemotherapy plus radiotherapy with chemotherapy plus surgery plus radiotherapy in locally advanced resectable hypopharyngeal carcinomas.
    The Laryngoscope, 1997, Volume: 107, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy,

1997
[Hyperfractionated accelerated simultaneous radiochemotherapy in advanced hypopharyngeal carcinomas. Survival rate, retained function quality of life in a phase II study].
    HNO, 1998, Volume: 46, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Co

1998
Concomitant b.i.d. radiotherapy and chemotherapy with cisplatin and 5-fluorouracil in unresectable squamous-cell carcinoma of the pharynx: clinical and pharmacological data of a French multicenter phase II study.
    International journal of radiation oncology, biology, physics, 1998, Sep-01, Volume: 42, Issue:2

    Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamo

1998
Neoadjuvant therapy for organ preservation in head and neck cancer.
    The Laryngoscope, 2000, Volume: 110, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Chemot

2000
Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
    International journal of radiation oncology, biology, physics, 2001, Aug-01, Volume: 50, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Co

2001
Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
    International journal of radiation oncology, biology, physics, 2001, Aug-01, Volume: 50, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Co

2001
Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
    International journal of radiation oncology, biology, physics, 2001, Aug-01, Volume: 50, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Co

2001
Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
    International journal of radiation oncology, biology, physics, 2001, Aug-01, Volume: 50, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Co

2001
Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
    International journal of radiation oncology, biology, physics, 2001, Aug-01, Volume: 50, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Co

2001
Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
    International journal of radiation oncology, biology, physics, 2001, Aug-01, Volume: 50, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Co

2001
Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
    International journal of radiation oncology, biology, physics, 2001, Aug-01, Volume: 50, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Co

2001
Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
    International journal of radiation oncology, biology, physics, 2001, Aug-01, Volume: 50, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Co

2001
Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
    International journal of radiation oncology, biology, physics, 2001, Aug-01, Volume: 50, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Co

2001

Other Studies

72 other studies available for fluorouracil and Hypopharyngeal Cancer

ArticleYear
Biomarker discovery for practice of precision medicine in hypopharyngeal cancer: a theranostic study on response prediction of the key therapeutic agents.
    BMC cancer, 2022, Jul-16, Volume: 22, Issue:1

    Topics: Cell Adhesion Molecules, Neuronal; Cisplatin; Docetaxel; Fluorouracil; Humans; Hypopharyngeal Neopla

2022
Long-term outcomes of induction chemotherapy followed by chemoradiotherapy vs chemoradiotherapy alone as treatment of unresectable head and neck cancer: follow-up of the Spanish Head and Neck Cancer Group (TTCC) 2503 Trial.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2021, Volume: 23, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Clinical Trials, Phase

2021
Incessant Atrial Tachycardia Following Combination Chemotherapy with Cetuximab, Cisplatin and 5-Fluorouracil for Hypopharyngeal Cancer.
    Cardiovascular toxicology, 2021, Volume: 21, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Catheter Ablation; Cetuximab; Cisplatin; Elect

2021
Rational choice of induction chemotherapy-based larynx preservation for hypopharyngeal cancer.
    Acta oto-laryngologica, 2018, Volume: 138, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Cause of Death;

2018
Dynamic changes in chemosensitivity immune predictors in patients with hypopharyngeal cancer treated with induction chemotherapy.
    Head & neck, 2019, Volume: 41, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; CD4-Positive

2019
The effectiveness of chemoradiation therapy and salvage surgery for hypopharyngeal squamous cell carcinoma.
    Japanese journal of clinical oncology, 2013, Volume: 43, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe

2013
p27 and BCL2 expression predicts response to chemotherapy in head and neck squamous cell carcinomas.
    Oral oncology, 2014, Volume: 50, Issue:2

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, S

2014
Survival and selected outcomes of older adults with locally advanced head/neck cancer treated with chemoradiation therapy.
    Journal of geriatric oncology, 2013, Volume: 4, Issue:4

    Topics: Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Che

2013
Definitive radiotherapy for early-stage hypopharyngeal squamous cell carcinoma.
    European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2015, Volume: 272, Issue:8

    Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free Su

2015
[Non-surgical combined modality treatments for laryngeal organ preservation in advanced hypopharyngeal carcinoma].
    Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery, 2014, Volume: 49, Issue:7

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto

2014
EGR1 regulates radiation-induced apoptosis in head and neck squamous cell carcinoma.
    Oncology reports, 2015, Volume: 33, Issue:4

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regula

2015
Nutritional status and feeding-tube placement in patients with locally advanced hypopharyngeal cancer included in an induction chemotherapy-based larynx preservation program.
    European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2016, Volume: 273, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous

2016
Chemoselection combined with alternating chemoradiotherapy or surgery for hypopharyngeal cancer.
    The Laryngoscope, 2016, Volume: 126, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Protocols; Chemoradiotherapy; Cisplatin; Combined

2016
Definitive Radiotherapy Following Induction Chemotherapy for Hypopharyngeal Cancer: Selecting Candidates for Organ-Preserving Treatment Based on the Response to Induction Chemotherapy.
    The Kurume medical journal, 2016, Volume: 62, Issue:1-2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel; Femal

2016
[Analysis of clinical factors for the efficacy of TPF in treating hypopharyngeal carcinoma].
    Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery, 2015, Volume: 29, Issue:19

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Humans; Hypopharyngeal Neop

2015
Salivary Cytokine Levels and Oral Mucositis in Head and Neck Cancer Patients Treated With Chemotherapy and Radiation Therapy.
    International journal of radiation oncology, biology, physics, 2016, 12-01, Volume: 96, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma; Carcinoma,

2016
Clinical Outcomes of Hypopharyngeal Cancer Receiving Definitive Radiotherapy with Concurrent Chemotherapy.
    Anticancer research, 2017, Volume: 37, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Deglutition Diso

2017
Additive effects of oral fluoropyrimidine derivative S-1 and radiation on human hypopharyngeal cancer xenografts.
    Acta oto-laryngologica, 2008, Volume: 128, Issue:8

    Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Combined Modality Therapy; Drug Comb

2008
Chemoradiotherapy laryngeal preservation for advanced hypopharyngeal cancer.
    Japanese journal of clinical oncology, 2008, Volume: 38, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co

2008
Clinical predictors of larynx preservation after multiagent concurrent chemoradiotherapy.
    Head & neck, 2008, Volume: 30, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Fema

2008
Searching for less toxic larynx preservation: a need for common definitions and metrics.
    Journal of the National Cancer Institute, 2009, Feb-04, Volume: 101, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci

2009
Weekly low-dose docetaxel-based chemoradiotherapy for locally advanced oropharyngeal or hypopharyngeal carcinoma: a retrospective, single-institution study.
    International journal of radiation oncology, biology, physics, 2010, Feb-01, Volume: 76, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Antineoplastic Combined

2010
[A case of double advanced cancer with esophageal and hypopharyngeal carcinoma responding completely to combination chemotherapy of docetaxel/5-fluorouracil and nedaplatin with radiation].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Docetaxel; Esophage

2009
Long-term results of intensity-modulated radiotherapy concomitant with chemotherapy for hypopharyngeal carcinoma aimed at laryngeal preservation.
    BMC cancer, 2010, Mar-18, Volume: 10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous

2010
Weekly volume and dosimetric changes during chemoradiotherapy with intensity-modulated radiation therapy for head and neck cancer: a prospective observational study.
    International journal of radiation oncology, biology, physics, 2010, Volume: 76, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Stem; Cisplatin; Combined Modality Therapy; Fl

2010
Intensity modulated radiotherapy with concurrent chemotherapy for larynx preservation of advanced resectable hypopharyngeal cancer.
    Radiation oncology (London, England), 2010, May-15, Volume: 5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D

2010
Long-term survival of induction chemotherapy plus surgery and postoperative radiotherapy in patients with stage IV hypopharyngeal cancer.
    Anti-cancer drugs, 2010, Volume: 21, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; D

2010
[Successfully treated case of hypopharyngeal and cervical esophageal squamous cell carcinoma with laryngeal preservation].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:12

    Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic

2010
Evaluation of overall tumor cellularity after neoadjuvant chemotherapy in patient with locally advanced hypopharyngeal cancer.
    European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2012, Volume: 269, Issue:11

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C

2012
[Concurrent chemoradiotherapy with either CDDP or CDGP, plus 5-FU for squamous cell carcinoma of the oropharynx and hypopharynx].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2012, Volume: 39, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous

2012
Laryngeal preservation in advanced piriform sinus squamous cell carcinomas using superselective intra-arterial chemoradiation therapy with three agents.
    Acta oto-laryngologica, 2013, Volume: 133, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe

2013
[A case of hypopharyngeal carcinoma in which a complete response to chemotherapy was achieved with docetaxel, cisplatin, 5-FU and levofolinate].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:10

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel

2002
[Radiation-induced mucositis and neutrophil granulocytes in oral mucosa].
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2003, Volume: 179, Issue:10

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Combined Modality Therapy

2003
[Four cases of hypopharyngeal cancer treated with docetaxel, cisplatin, and 5-FU followed by radiotherapy and/or neck dissection].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Docetaxel;

2004
[Treatment of hypopharyngeal carcinomas--an institutional analysis of the results of FAR radiochemotherapy, radical resection, and free jejunum flap reconstruction and the indication of neck dissection].
    Nihon Jibiinkoka Gakkai kaiho, 2004, Volume: 107, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cervicoplasty; Cineradiography; Female; Fluor

2004
Delayed radiation myelopathy after concurrent chemoradiation for hypopharyngeal-esophageal carcinoma.
    Acta oncologica (Stockholm, Sweden), 2005, Volume: 44, Issue:2

    Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Degluti

2005
Effects of cisplatin, 5-fluorouracil, and radiation on cell cycle regulation and apoptosis in the hypopharyngeal carcinoma cell line.
    Chemotherapy, 2005, Volume: 51, Issue:2-3

    Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle; Cell Cycle Proteins; Cell Li

2005
Survival impact of planned restaging and early surgical salvage following definitive chemoradiation for locally advanced squamous cell carcinomas of the oropharynx and hypopharynx.
    American journal of clinical oncology, 2005, Volume: 28, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carboplatin;

2005
Intensity-modulated radiation therapy in head and neck cancers: dosimetric advantages and update of clinical results.
    American journal of clinical oncology, 2005, Volume: 28, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino

2005
[Concurrent chemoradiotherapy for advanced hypopharyngeal cancer].
    Nihon Jibiinkoka Gakkai kaiho, 2005, Volume: 108, Issue:10

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco

2005
Reversible impairment of auditory callosal pathway in 5-fluorouracil-induced leukoencephalopathy: parallel changes in function and imaging.
    Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology, 2006, Volume: 27, Issue:5

    Topics: Antimetabolites, Antineoplastic; Auditory Pathways; Corpus Callosum; Dementia, Vascular; Dichotic Li

2006
Potential use of alexidine dihydrochloride as an apoptosis-promoting anticancer agent.
    Molecular cancer therapeutics, 2006, Volume: 5, Issue:9

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biguanide

2006
Concurrent chemotherapy and intensity-modulated radiotherapy for locoregionally advanced laryngeal and hypopharyngeal cancers.
    International journal of radiation oncology, biology, physics, 2007, Oct-01, Volume: 69, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy;

2007
Concurrent chemoradiotherapy for T4 patients with hypopharyngeal and laryngeal squamous cell carcinomas.
    Auris, nasus, larynx, 2007, Volume: 34, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co

2007
Influence of delayed tumor clearance on reliability of complete response rate in chemoradiotherapy for head and neck cancer.
    Japanese journal of clinical oncology, 2007, Volume: 37, Issue:8

    Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Fluorouracil;

2007
Treatment results and prognostic factors in locally advanced hypopharyngeal cancer.
    Acta oto-laryngologica, 2008, Volume: 128, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co

2008
[Treatment results of concurrent chemoradiotherapy with CDDP or CDGP plus 5-FU for carcinoma of the oropharynx and hypopharynx].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:9

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod

2007
Concurrent chemoradiotherapy with cisplatin and fluorouracil for locally advanced hypopharyngeal carcinoma.
    Acta oto-laryngologica, 2008, Volume: 128, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co

2008
Chemotherapeutic management of head and neck malignancies with positron emission tomography.
    Archives of otolaryngology--head & neck surgery, 1995, Volume: 121, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Deoxyglucose; F

1995
Regarding Keane et al.'s randomized trial comparing radiation alone to concomitant infusional 5-flurorouracil, bolus mitomycin-C and split-course radiation.
    International journal of radiation oncology, biology, physics, 1994, Jan-15, Volume: 28, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Hypopharyngeal Neoplasms; Lary

1994
Prognostic value of tumor regression during radiotherapy or chemoradiotherapy for advanced head and neck cancers: regarding Jaulerry et al. IJROBP 33(2):271-279; 1995.
    International journal of radiation oncology, biology, physics, 1996, Mar-01, Volume: 34, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Fluorouracil;

1996
[Perioperative chemotherapy of squamous cell carcinoma of the hypopharynx].
    Bulletin du cancer. Radiotherapie : journal de la Societe francaise du cancer : organe de la societe francaise de radiotherapie oncologique, 1996, Volume: 83, Issue:2

    Topics: Actuarial Analysis; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemot

1996
Determination of tumor-related factors of influence on the uptake of the monoclonal antibody 323/A3 in experimental human ovarian cancer.
    International journal of cancer, 1997, Apr-10, Volume: 71, Issue:2

    Topics: Animals; Antibodies, Monoclonal; Antigens, Neoplasm; Biomarkers, Tumor; Carcinoembryonic Antigen; Ce

1997
[Thymidylate synthase expression in patients with hypopharyngeal carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1998, Volume: 25, Issue:7

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Female; F

1998
Reconstruction with free jejunal autograft after circumferential pharyngolaryngectomy: eighty-three cases.
    The Annals of otology, rhinology, and laryngology, 1998, Volume: 107, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma; Cisplatin; Combined Modality Therapy; Fem

1998
Cytomegalovirus colitis after administration of docetaxel-5-fluorouracil-cisplatin chemotherapy for locally advanced hypopharyngeal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1999, Volume: 10, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Colitis; Cytome

1999
Rapidly progressive glomerulonephritis and carcinoma of the hypopharynx.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2001, Volume: 37, Issue:1

    Topics: Brachytherapy; Fluorouracil; Glomerulonephritis; Humans; Hypopharyngeal Neoplasms; Male; Middle Aged

2001
Concomitant twice-a-day radiotherapy and chemotherapy in unresectable head and neck cancer patients: A long-term quality of life analysis.
    Head & neck, 2001, Volume: 23, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; En

2001
[A case of advanced hypopharyngeal carcinoma successfully treated with superselective intra-arterial infusion of docetaxel].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:2

    Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma,

2002
Concomitant chemoradiotherapy in pyriform sinus carcinoma.
    Archives of otolaryngology--head & neck surgery, 2002, Volume: 128, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell;

2002
[Induction chemotherapy and larynx preservation: is such practice useful?].
    Bulletin du cancer, 2002, Volume: 89, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali

2002
[Vestibulotoxic effects of the cytostatic drug carboplatin in patients with head and neck tumors].
    HNO, 1992, Volume: 40, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Administration Schedule; Fluoroura

1992
[Evaluating the effectiveness of chemotherapy in patients with head-neck tumors using positron emission tomography (PET scan)].
    HNO, 1992, Volume: 40, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Glucose; Carcinoma; Carcinoma, Squamous Cell;

1992
[Antineoplastic effectiveness and unwanted side effects of polychemotherapy of extensive oro- and hypopharyngeal cancers--results of a prospective therapy study with 5-FU/cisplatin versus 5-FU/carboplatin].
    Laryngo- rhino- otologie, 1992, Volume: 71, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Audiometry, Pure-Tone; Auditory Threshold; Bone Marr

1992
Larynx preservation using induction chemotherapy plus radiation therapy as an alternative to laryngectomy in advanced head and neck cancer. A long-term follow-up report.
    American journal of clinical oncology, 1991, Volume: 14, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cause of Death; Cisplatin; Combined

1991
[Clinical evaluation of hypopharyngeal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1991, Volume: 18, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Combined Modality Therapy; Flu

1991
[Simultaneous radiotherapy and chemotherapy with cisplatin and 5-fluorouracil in advanced head and neck tumors].
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 1991, Volume: 167, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; F

1991
[Induction chemotherapy in cancer of the upper respiratory and digestive tract. Preliminary results of the protocol combining cisplatin, 5-fluorouracil and bleomycin (CFB)].
    Annales d'oto-laryngologie et de chirurgie cervico faciale : bulletin de la Societe d'oto-laryngologie des hopitaux de Paris, 1985, Volume: 102, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Comb

1985
Pretreatment with chemotherapy in patients with advanced head and neck cancer.
    The Journal of otolaryngology, 1985, Volume: 14, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Cycl

1985
A pilot study of mitomycin-C/5-fluorouracil infusion combined with split course radiation therapy for carcinomas of the larynx and hypopharynx.
    The Journal of otolaryngology, 1986, Volume: 15, Issue:5

    Topics: Adult; Aged; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Therapy, Combination; Female;

1986
Induction chemotherapy with cis-platinum and 5-fluorouracil for squamous cell carcinoma of the head and neck.
    British journal of cancer, 1986, Volume: 54, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous

1986
Synergistic combination therapy of 5-fluorouracil, vitamin A, and cobalt-60 radiation for head and neck tumors--antitumor combination therapy with vitamin A.
    Auris, nasus, larynx, 1985, Volume: 12 Suppl 2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cobalt Radioisotopes; Combined Modality

1985